Macrolides in Chronic Inflammatory Skin Disorders
Long-term therapy with the macrolide antibiotic erythromycin was shown to alter the clinical course of diffuse panbronchiolitis in the late 1980s. Since that time, macrolides have been found to have a large number of anti-inflammatory properties in addition to being antimicrobials. These observation...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2012/159354 |
id |
doaj-5e5cdd1a0c0248439018a6cd5bdacd8e |
---|---|
record_format |
Article |
spelling |
doaj-5e5cdd1a0c0248439018a6cd5bdacd8e2020-11-25T00:37:00ZengHindawi LimitedMediators of Inflammation0962-93511466-18612012-01-01201210.1155/2012/159354159354Macrolides in Chronic Inflammatory Skin DisordersAbdullateef A. Alzolibani0Khaled Zedan1Dermatology Department, College of Medicine, Qassim University, P.O. Box 30109, Buraidah 51477, Saudi ArabiaPediatric Department, College of Medicine, Qassim University, P.O. Box 30109, Buraidah 51477, Saudi ArabiaLong-term therapy with the macrolide antibiotic erythromycin was shown to alter the clinical course of diffuse panbronchiolitis in the late 1980s. Since that time, macrolides have been found to have a large number of anti-inflammatory properties in addition to being antimicrobials. These observations provided the rationale for many studies performed to assess the usefulness of macrolides in other inflammatory diseases including skin and hair disorders, such as rosacea, psoriasis, pityriasis rosea, alopecia areata, bullous pemphigoid, and pityriasis lichenoides. This paper summarizes a collection of clinical studies and case reports dealing with the potential benefits of macrolides antibiotics in the treatment of selected dermatoses which have primarily been classified as noninfectious and demonstrating their potential for being disease-modifying agents.http://dx.doi.org/10.1155/2012/159354 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abdullateef A. Alzolibani Khaled Zedan |
spellingShingle |
Abdullateef A. Alzolibani Khaled Zedan Macrolides in Chronic Inflammatory Skin Disorders Mediators of Inflammation |
author_facet |
Abdullateef A. Alzolibani Khaled Zedan |
author_sort |
Abdullateef A. Alzolibani |
title |
Macrolides in Chronic Inflammatory Skin Disorders |
title_short |
Macrolides in Chronic Inflammatory Skin Disorders |
title_full |
Macrolides in Chronic Inflammatory Skin Disorders |
title_fullStr |
Macrolides in Chronic Inflammatory Skin Disorders |
title_full_unstemmed |
Macrolides in Chronic Inflammatory Skin Disorders |
title_sort |
macrolides in chronic inflammatory skin disorders |
publisher |
Hindawi Limited |
series |
Mediators of Inflammation |
issn |
0962-9351 1466-1861 |
publishDate |
2012-01-01 |
description |
Long-term therapy with the macrolide antibiotic erythromycin was shown to alter the clinical course of diffuse panbronchiolitis in the late 1980s. Since that time, macrolides have been found to have a large number of anti-inflammatory properties in addition to being antimicrobials. These observations provided the rationale for many studies performed to assess the usefulness of macrolides in other inflammatory diseases including skin and hair disorders, such as rosacea, psoriasis, pityriasis rosea, alopecia areata, bullous pemphigoid, and pityriasis lichenoides. This paper summarizes a collection of clinical studies and case reports dealing with the potential benefits of macrolides antibiotics in the treatment of selected dermatoses which have primarily been classified as noninfectious and demonstrating their potential for being disease-modifying agents. |
url |
http://dx.doi.org/10.1155/2012/159354 |
work_keys_str_mv |
AT abdullateefaalzolibani macrolidesinchronicinflammatoryskindisorders AT khaledzedan macrolidesinchronicinflammatoryskindisorders |
_version_ |
1725303100404662272 |